Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker IMCR · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma NCT03070392 · Uveal Melanoma IMCgp100, Dacarbazine | IMCR Immunocore Ltd | Phase 2 | Completed | 378 | Oct 13, 2020 | Registry ↗ |
| Mar 25, 2026 | Study of IMC-S118AI in Type 1 Diabetes NCT07493122 · Type 1 Diabetes, Type 1 Diabetes (T1D) IMC-S118AI | IMCR Immunocore Ltd | Phase 1 | Not yet recruiting | 154 | Nov 2030 | Registry ↗ |
| Mar 6, 2026 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors NCT04262466 · Select Advanced Solid Tumors Brenetafusp, Brenetafusp and pembrolizumab | IMCR Immunocore Ltd | Phase 1/2 | Active, not recruiting | 410 | Oct 2026 | Registry ↗ |
| Feb 25, 2026 | Study of IMC-P115C in Advanced PRAME-Positive Cancers NCT07156136 · PRAME Positive, Cancer IMC-P115C | IMCR Immunocore Ltd | Phase 1 | Recruiting | 140 | Sep 30, 2027 | Registry ↗ |
| Feb 25, 2026 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-30… NCT06112314 · Advanced Melanoma Brenetafusp, Nivolumab | IMCR Immunocore Ltd | Phase 3 | Recruiting | 680 | Oct 16, 2027 | Registry ↗ |
| Feb 25, 2026 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) NCT05549297 · Advanced Melanoma Tebentafusp, Tebentafusp with Pembrolizumab | IMCR Immunocore Ltd | Phase 3 | Recruiting | 540 | Mar 2028 | Registry ↗ |
| Jan 28, 2026 | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers NCT06840119 · Cancer, HLA-A*02:01-positive IMC-R117C, Chemotherapy drug | IMCR Immunocore Ltd | Phase 1/2 | Recruiting | 600 | Nov 30, 2026 | Registry ↗ |
| Oct 18, 2024 | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab NCT03973333 · Select Advanced Solid Tumors IMC-C103C, Atezolizumab | IMCR Immunocore Ltd | Phase 1/2 | Withdrawn | 0 | Sep 25, 2023 | Registry ↗ |
| Oct 15, 2024 | Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection NCT05867056 · Hepatitis B, Chronic IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascendi… | IMCR Immunocore Ltd | Phase 1 | Withdrawn | 0 | Sep 10, 2024 | Registry ↗ |
| Jul 24, 2024 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cut… NCT02535078 · Malignant Melanoma Tebentafusp (IMCgp100) | IMCR Immunocore Ltd | Phase 1/2 | Withdrawn | 0 | Jun 19, 2023 | Registry ↗ |
| Mar 21, 2023 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uvea… NCT02570308 · Uveal Melanoma IMCgp100 | IMCR Immunocore Ltd | Phase 1/2 | Completed | 146 | Mar 20, 2020 | Registry ↗ |
| Mar 11, 2022 | Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers NCT03515551 · Select Advanced Solid Tumors IMCnyeso | IMCR Immunocore Ltd | Phase 1/2 | Terminated | 29 | May 10, 2021 | Registry ↗ |
| Jan 21, 2022 | A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp NCT04960891 · Uveal Melanoma Tebentafusp | IMCR Immunocore Ltd | — | Available | — | — | Registry ↗ |
| Jul 27, 2020 | IMCgp100-401 Rollover Study NCT02889861 · Malignant Melanoma IMCgp100 | IMCR Immunocore Ltd | Phase 2 | Terminated | 3 | Apr 22, 2019 | Registry ↗ |
| Jul 8, 2020 | Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma NCT01211262 · Malignant Melanoma IMCgp100 | IMCR Immunocore Ltd | Phase 1 | Completed | 84 | Feb 16, 2016 | Registry ↗ |
15 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:56 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances